Pharmacogenetic markers of development of angioneurotic edema as a secondary side effect to enalapril in patients with essential arterial hypertension.

Pub Date : 2024-01-01 DOI:10.3233/JRS-230006

Ivan V Sychev, Natalia P Denisenko, Anastasiya A Kachanova, Anna V Lapshtaeva, Sherzod P Abdullaev, Ludmila N Goncharova, Karin B Mirzaev, Dmitry A Sychev

{"title":"Pharmacogenetic markers of development of angioneurotic edema as a secondary side effect to enalapril in patients with essential arterial hypertension.","authors":"Ivan V Sychev, Natalia P Denisenko, Anastasiya A Kachanova, Anna V Lapshtaeva, Sherzod P Abdullaev, Ludmila N Goncharova, Karin B Mirzaev, Dmitry A Sychev","doi":"10.3233/JRS-230006","DOIUrl":null,"url":null,"abstract":"Background: Angioneurotic edema is the most dangerous complication in angiotensin-converting enzyme inhibitors (ACEIs) therapy. Based on the current data, the clinical and genetic predictors of angioedema development are still understudied, which demonstrates the relevance of this study.Objective: To reveal the pharmacogenetic predictors of the angioedema as a secondary side effect to enalapril in patients with essential arterial hypertension.Methods: The study enrolled 111 subjects randomized into two groups: study group, patients with the angioedema as a secondary side effect to enalapril; and control group, patients without adverse drug reaction. All patients underwent pharmacogenetic testing.Results: An association between the development of the angioneurotic edema and the genotypes AA rs2306283 of gene SLCO1B1, TT rs4459610 of gene ACE, and CC rs1799722 of gene BDKRB2 in patients was revealed.Conclusion: The findings justify further investigations of the revealed genetic predictors of angioedema with larger-size patient populations.","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/JRS-230006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Angioneurotic edema is the most dangerous complication in angiotensin-converting enzyme inhibitors (ACEIs) therapy. Based on the current data, the clinical and genetic predictors of angioedema development are still understudied, which demonstrates the relevance of this study.

Objective: To reveal the pharmacogenetic predictors of the angioedema as a secondary side effect to enalapril in patients with essential arterial hypertension.

Methods: The study enrolled 111 subjects randomized into two groups: study group, patients with the angioedema as a secondary side effect to enalapril; and control group, patients without adverse drug reaction. All patients underwent pharmacogenetic testing.

Results: An association between the development of the angioneurotic edema and the genotypes AA rs2306283 of gene SLCO1B1, TT rs4459610 of gene ACE, and CC rs1799722 of gene BDKRB2 in patients was revealed.

Conclusion: The findings justify further investigations of the revealed genetic predictors of angioedema with larger-size patient populations.

查看原文

原发性动脉高压患者血管神经性水肿的药物遗传学标志物依那普利的继发副作用。

背景：血管紧张素转换酶抑制剂（ACEIs）治疗中，血管神经性水肿是最危险的并发症。根据目前的数据，血管性水肿发展的临床和遗传预测因素仍然研究不足，这证明了这项研究的相关性。目的：揭示血管性水肿作为依那普利继发副作用在原发性动脉高压患者中的药物遗传学预测因素。方法：本研究将111名受试者随机分为两组：研究组，以血管性水肿为依那普利次要副作用的患者；对照组为无药物不良反应患者。所有患者均接受了药物遗传学检查。结果：SLCO1B1基因AA rs2306283、ACE基因TT rs4459610和BDKRB2基因CC rs1799722基因型与血管神经性水肿的发生有关。结论：这些发现证明了在更大的患者群体中进一步研究血管性水肿的遗传预测因素是合理的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文